 In animal studies of meningitis caused by Streptococcus pneumoniae , linezolid was found to penetrate well into cerebrospinal fluid , but its effectiveness was inferior to that of other antibiotics . There does not appear to be enough high @-@ quality evidence to support the routine use of linezolid to treat bacterial meningitis . Nonetheless , it has been used successfully in many cases of central nervous system infection — including meningitis — caused by susceptible bacteria , and has also been suggested as a reasonable choice for this indication when treatment options are limited or when other antibiotics have failed . The guidelines of the Infectious Diseases Society of America recommend linezolid as the first @-@ line drug of choice for VRE meningitis , and as an alternative to vancomycin for MRSA meningitis . Linezolid appears superior to vancomycin in treating community @-@ acquired MRSA infections of the central nervous system , although very few cases of such infections have been published ( as of 2009 ) . 
